Antigen Presentation And Cytokines - USMLE Step 1

SECTION 1

Historical Context & Motivation

The concept that the immune system must first "see" a pathogen before mounting a targeted defense has been central to immunology since the late nineteenth century. Early investigators such as Élie Metchnikoff observed that macrophages ingested foreign material, but the molecular logic linking phagocytosis to the activation of lymphocytes remained elusive for decades. The discovery of the major histocompatibility complex (MHC) and soluble mediators called cytokines eventually provided the mechanistic bridge between innate recognition and adaptive immunity. Understanding how antigen presentation and cytokine signaling work in concert is essential for grasping immunopathology, vaccine design, transplant rejection, and autoimmunity—topics tested heavily on USMLE Step 1.

1884 • Metchnikoff's Phagocyte Theory

Élie Metchnikoff proposed that phagocytic cells actively engulf and destroy pathogens, laying groundwork for innate immune recognition.

1948 • Discovery of MHC in Transplant Rejection

George Snell's work on graft rejection in mice identified histocompatibility loci, later termed the major histocompatibility complex (MHC).

1973 • MHC Restriction Defined

Rolf Zinkernagel and Peter Doherty demonstrated that T cells only recognize viral antigens when presented by self-MHC molecules, establishing the principle of MHC restriction.

1986 • Th1/Th2 Cytokine Paradigm

Timothy Mosmann and Robert Coffman identified distinct cytokine profiles (IFN-γ versus IL-4) produced by helper T-cell subsets, creating the Th1/Th2 framework that remains clinically relevant today.

2011 • Nobel Prize for Dendritic Cell Biology

Ralph Steinman received the Nobel Prize for his discovery of the dendritic cell and its role as the premier professional antigen-presenting cell (APC) that initiates adaptive immune responses.

The central question that antigen presentation resolves is deceptively simple: How does a T cell, which cannot bind free antigen, learn about intracellular or extracellular pathogens? The answer lies in the MHC-peptide complex displayed on APC surfaces and the cytokine milieu that determines the downstream effector phenotype. These two systems—presentation and signaling—are inseparable in clinical immunology.

SECTION 2

Core Principles & Definitions

Antigen presentation and cytokine signaling operate through a coordinated set of principles that connect innate detection to adaptive effector responses. Grasping these foundational ideas is critical before examining the molecular details of MHC class I versus class II pathways, professional versus non-professional APCs, and the cytokine networks that polarize T-cell differentiation.

MHC Restriction

T cells recognize antigenic peptides only when complexed with self-MHC molecules. CD8⁺ T cells are restricted to MHC class I (present on all nucleated cells), while CD4⁺ T cells are restricted to MHC class II (expressed mainly on professional APCs).

Professional Antigen-Presenting Cells

Three cell types—dendritic cells, macrophages, and B cells—constitutively express MHC II and co-stimulatory molecules (CD80/CD86), making them uniquely capable of activating naïve CD4⁺ T cells.

Two-Signal Hypothesis

Full T-cell activation requires two signals: Signal 1 from the TCR–MHC-peptide interaction and Signal 2 from co-stimulatory molecules (e.g., B7 on APC binding CD28 on T cell). Without Signal 2, T cells become anergic (tolerized).

Cytokine-Directed Polarization

The cytokine environment during T-cell activation (Signal 3) determines effector differentiation. For example, IL-12 drives Th1, IL-4 drives Th2, and TGF-β + IL-6 drives Th17. This is critical for pathogen-appropriate immunity.

Cross-Presentation

Dendritic cells uniquely load exogenous antigens onto MHC class I molecules through cross-presentation, enabling CD8⁺ cytotoxic T-cell responses against viruses and tumors that do not directly infect APCs.

✦

KEY TAKEAWAY

Think of antigen presentation like a restaurant's kitchen-to-table system. The APC is the kitchen that processes raw ingredients (antigens) into presentable dishes (MHC-peptide complexes), the MHC molecule is the serving plate, and the cytokines are the sommelier's wine pairing that determines which flavor profile (Th1, Th2, Th17) the immune response takes. Without the correct plate (MHC restriction) and wine pairing (cytokine milieu), the meal (adaptive response) either fails to arrive or is inappropriate for the occasion.

SECTION 3

Visual Overview of Antigen Presentation Pathways

The two classical antigen presentation pathways differ in their source of antigen, the MHC class used, the intracellular compartments involved, and the T-cell subset activated. The diagram below contrasts the MHC class I (endogenous) pathway with the MHC class II (exogenous) pathway. Note how cytosolic versus endosomal processing leads to fundamentally different immune outcomes.

Left panel: The endogenous (MHC class I) pathway processes intracellular proteins via the proteasome, transports peptides through the TAP transporter into the ER, loads them onto MHC I + β₂-microglobulin, and presents them to CD8⁺ T cells. Right panel: The exogenous (MHC class II) pathway takes up extracellular antigens by endocytosis, degrades them in acidified endosomes, replaces the CLIP fragment with antigenic peptide (via HLA-DM), and presents the complex to CD4⁺ T cells.

Several high-yield details emerge from this side-by-side comparison. In the MHC I pathway, the proteasome and TAP transporter are essential; defects in TAP cause bare lymphocyte syndrome type I. In the MHC II pathway, the invariant chain (Ii) blocks premature peptide binding in the ER, and HLA-DM catalyzes the exchange of CLIP for high-affinity antigenic peptide within the MIIC compartment. These molecular players are commonly tested in board-style questions.

SECTION 4

Molecular Mechanisms of Antigen Processing

MHC Class I Processing: The Endogenous Pathway

All nucleated cells continuously sample their own proteome through the ubiquitin-proteasome system. Cytosolic proteins—whether normal self-proteins, viral proteins synthesized during infection, or tumor neoantigens—are tagged with polyubiquitin chains and fed into the proteasome, a barrel-shaped protease complex. The resulting peptide fragments, typically 8–10 amino acids in length, are transported from the cytosol into the endoplasmic reticulum (ER) lumen by the transporter associated with antigen processing (TAP), a heterodimeric ABC transporter composed of TAP1 and TAP2 subunits. Inside the ER, the peptide is loaded onto newly synthesized MHC I heavy chain–β₂-microglobulin complexes with the help of chaperones including tapasin, calreticulin, and ERp57. The stabilized MHC I–peptide complex then transits through the Golgi apparatus to the cell surface, where it can be surveyed by CD8⁺ cytotoxic T lymphocytes.

MHC Class II Processing: The Exogenous Pathway

Professional APCs internalize extracellular antigens by receptor-mediated endocytosis, phagocytosis, or macropinocytosis. The internalized material encounters progressively acidic endosomal compartments containing cathepsins and other acid proteases that degrade proteins into peptides of 13–25 amino acids. Meanwhile, MHC class II αβ heterodimers are synthesized in the ER, where they associate with the invariant chain (Ii, CD74). The invariant chain serves two functions: it blocks the peptide-binding groove to prevent premature loading of ER-resident peptides, and it contains targeting signals that direct the MHC II–Ii complex from the ER through the Golgi into the MHC class II compartment (MIIC). In the MIIC, the invariant chain is progressively cleaved, leaving behind a short remnant called CLIP (class II–associated invariant chain peptide) seated in the groove. The non-classical MHC II molecule HLA-DM then catalyzes the removal of CLIP and facilitates the loading of high-affinity antigenic peptides. The peptide-loaded MHC II complex is transported to the cell surface for recognition by CD4⁺ T helper cells.

Cross-Presentation: A Special Case

Dendritic cells possess the unique ability to load exogenous antigens onto MHC class I molecules through a process called cross-presentation. This is immunologically critical because many viruses and tumor cells do not directly infect dendritic cells. In cross-presentation, phagocytosed material escapes from the endosome into the cytosol, enters the proteasome, and is loaded onto MHC I via the standard TAP-dependent route. The result is activation of CD8⁺ cytotoxic T cells against pathogens or tumors that the dendritic cell has never been directly infected by—a mechanism central to antitumor immunity and the rationale for dendritic cell-based cancer vaccines.

💡

High-Yield Board Tip

A USMLE-style question may describe a patient with recurrent sinopulmonary infections and absent MHC I surface expression. Think: TAP deficiency (Bare Lymphocyte Syndrome Type I). Alternatively, absent MHC II expression with severe combined immunodeficiency suggests Bare Lymphocyte Syndrome Type II due to a defect in the CIITA transcription factor.

SECTION 5

Cytokine Networks & T-Cell Polarization

Once a naïve CD4⁺ T cell receives Signal 1 (TCR engagement with MHC II–peptide) and Signal 2 (co-stimulation via CD28–B7), the cytokine milieu (Signal 3) determines the trajectory of differentiation. Each T-helper subset secretes a characteristic cytokine profile, activates a signature transcription factor, and orchestrates a distinct arm of adaptive immunity. The following diagram and table summarize the major CD4⁺ T-helper subsets, their polarizing cytokines, master transcription factors, and signature effector cytokines.

Naïve CD4⁺ T cells differentiate into Th1 (via IL-12/IFN-γ, T-bet), Th2 (via IL-4, GATA-3), Th17 (via TGF-β + IL-6, RORγt), or Treg (via TGF-β + IL-2, FoxP3) subsets depending on the cytokine environment. Each subset produces signature effector cytokines and combats distinct pathogen types.

Subset	Polarizing Cytokine(s)	Transcription Factor	Effector Cytokines	Primary Function
Th1	IL-12, IFN-γ	T-bet	IFN-γ, IL-2, TNF-α	Macrophage activation; intracellular pathogens
Th2	IL-4	GATA-3	IL-4, IL-5, IL-10, IL-13	IgE class switching; eosinophil activation; parasites & allergy
Th17	TGF-β + IL-6 (+ IL-23)	RORγt	IL-17A, IL-17F, IL-22	Neutrophil recruitment; extracellular bacteria & fungi
Treg	TGF-β + IL-2	FoxP3	IL-10, TGF-β	Immune suppression; peripheral tolerance; prevention of autoimmunity
Tfh	IL-6, IL-21	Bcl-6	IL-21, IL-4	Germinal center reactions; B-cell help; affinity maturation

Major CD4⁺ T-Helper Subsets and Their Cytokine Profiles

An important principle for board questions is reciprocal inhibition between helper subsets. IFN-γ (Th1) inhibits Th2 differentiation, while IL-4 (Th2) inhibits Th1 differentiation. This cross-regulation explains why leprosy presents as a clinical spectrum: tuberculoid leprosy features a dominant Th1 response with granuloma formation, whereas lepromatous leprosy features a Th2-skewed response with high antibody titers but poor cell-mediated containment of Mycobacterium leprae.

SECTION 6

Worked Example: Clinical Vignette

The following worked example walks through a board-style clinical vignette to illustrate how knowledge of antigen presentation and cytokines is applied on USMLE Step 1.

Clinical Vignette: Recurrent Infections in a 6-Month-Old

1
Step 1 — Read the Stem

A 6-month-old boy presents with recurrent bacterial infections, failure to thrive, and chronic diarrhea. Flow cytometry of peripheral blood lymphocytes shows normal numbers of CD8⁺ T cells but markedly reduced CD4⁺ T cells. HLA typing reveals absent MHC class II expression on his monocytes. What is the most likely diagnosis?
2
Step 2 — Identify Key Findings

The vignette provides several critical clues: recurrent infections starting after maternal antibody waning (6 months), low CD4⁺ T cells with preserved CD8⁺ T cells, and absent MHC class II on APCs. Recall that CD4⁺ T cells are selected on MHC class II in the thymus (positive selection) and depend on MHC II for peripheral activation.

Absent MHC II → impaired CD4⁺ T-cell development and activation
3
Step 3 — Connect to Pathophysiology

MHC class II expression is regulated by the transcription factor CIITA (class II transactivator) and the RFX transcription factor complex. A defect in any of these regulators leads to absent MHC II expression on all cell types that normally express it, including dendritic cells, macrophages, B cells, and thymic epithelial cells. Without MHC II in the thymus, positive selection of CD4⁺ T cells fails, leading to profound CD4⁺ lymphopenia.
4
Step 4 — Arrive at the Diagnosis

The diagnosis is Bare Lymphocyte Syndrome Type II, an autosomal recessive deficiency of MHC class II expression due to mutations in transcription factors (most commonly CIITA or RFX5/RFXAP/RFXANK). This results in a severe combined immunodeficiency phenotype affecting both humoral and cell-mediated immunity, since CD4⁺ T-helper function is required for optimal B-cell class switching and macrophage activation.

Answer: Bare Lymphocyte Syndrome Type II (MHC class II deficiency)
5
Step 5 — Distinguish from Type I

Bare Lymphocyte Syndrome Type I involves absent MHC class I expression, typically due to TAP1 or TAP2 mutations. These patients have reduced CD8⁺ T cells but intact CD4⁺ T cells and typically present with milder disease (recurrent sinopulmonary infections and necrotizing granulomas) because the CD4⁺ helper arm remains functional.

Type I = TAP defect → ↓MHC I → ↓CD8⁺; Type II = CIITA/RFX defect → ↓MHC II → ↓CD4⁺

SECTION 7

MHC Class I vs. MHC Class II: Side-by-Side Comparison

One of the most commonly tested frameworks on USMLE Step 1 is the comparison between MHC class I and MHC class II molecules. The following table consolidates all major differences in a format optimized for rapid board review.

Feature	MHC Class I	MHC Class II
HLA genes	HLA-A, HLA-B, HLA-C	HLA-DP, HLA-DQ, HLA-DR
Structure	α chain (α1, α2, α3) + β₂-microglobulin	α chain (α1, α2) + β chain (β1, β2)
Binding groove	Closed groove (α1 + α2); 8–10 aa peptides	Open groove (α1 + β1); 13–25 aa peptides
Cell expression	All nucleated cells + platelets (NOT RBCs)	Professional APCs (dendritic cells, macrophages, B cells)
Antigen source	Endogenous (intracellular: viral, tumor, self)	Exogenous (extracellular: bacterial, parasitic)
Processing machinery	Proteasome → TAP → ER loading	Endosome → Ii chain/CLIP → HLA-DM in MIIC
T-cell subset	CD8⁺ cytotoxic T cells	CD4⁺ helper T cells
Co-receptor	CD8 binds α3 domain	CD4 binds β2 domain
Clinical deficiency	BLS Type I (TAP defect)	BLS Type II (CIITA/RFX defect)

Comprehensive comparison of MHC Class I and MHC Class II

💡

MNEMONIC

Remember: MHC class I = 1 polypeptide chain encoded by the MHC locus (α) + β₂m, presents to CD8 (1 × 8 = 8). MHC class II = 2 chains (α + β), presents to CD4 (2 × 4 = 8, but the key is the "2" in class II matching the "2" chains). Also: "Rule of 8" — MHC I × CD8, MHC II × CD4, both products = 8.

SECTION 8

Connections to Clinical Immunology & Pharmacology

Antigen presentation and cytokine signaling are not isolated academic concepts—they represent the mechanistic basis for transplant rejection, autoimmune disease, immunodeficiency syndromes, and modern immunotherapy. Board questions frequently test your ability to connect these pathways to clinical scenarios and pharmacologic interventions.

Clinical Concept	Mechanism Involving Antigen Presentation / Cytokines	Pharmacologic Application
Transplant Rejection	Host T cells recognize donor MHC molecules (direct allorecognition) or donor peptides presented on host MHC (indirect). CD4⁺ Th1 cytokines (IFN-γ) drive acute cellular rejection.	Calcineurin inhibitors (tacrolimus, cyclosporine) block IL-2 production; anti-IL-2R mAb (basiliximab); belatacept blocks co-stimulation (CD80/86–CD28)
Autoimmunity (RA, MS)	Th17-driven IL-17 causes neutrophilic inflammation (RA synovitis). Th1/Th17 cells attack myelin in MS. HLA associations (e.g., HLA-DR4 in RA) affect which self-peptides are presented.	Anti-TNF agents (infliximab, adalimumab); anti-IL-17 (secukinumab); anti-IL-6R (tocilizumab); CTLA-4-Ig (abatacept)
Cancer Immunotherapy	Tumors downregulate MHC I to evade CD8⁺ CTLs. Tumor microenvironment enriched in Tregs and immunosuppressive cytokines (IL-10, TGF-β). Checkpoint molecules (PD-1, CTLA-4) inhibit T-cell activation.	Checkpoint inhibitors: anti-PD-1 (nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab), anti-CTLA-4 (ipilimumab); CAR-T cell therapy
Sepsis / Cytokine Storm	Massive release of TNF-α, IL-1, IL-6 by macrophages in response to PAMPs causes systemic inflammatory response, vasodilation, DIC, and multi-organ failure.	Anti-IL-6 (tocilizumab for cytokine release syndrome); corticosteroids (broadly suppress cytokine transcription via NF-κB inhibition)

Clinical applications of antigen presentation and cytokine concepts

Looking ahead to more advanced immunology, several emerging concepts build directly on the antigen presentation and cytokine framework covered here. Tumor neoantigen vaccines exploit the MHC I presentation of tumor-specific mutated peptides. Bispecific T-cell engagers (BiTEs) bypass the requirement for MHC-mediated antigen presentation by physically linking CD3 on T cells to tumor surface antigens. Understanding how and why these therapies were designed requires the conceptual foundation of MHC restriction, co-stimulation, and cytokine-mediated polarization that you have now mastered.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A dendritic cell presents a viral peptide to a naïve CD8⁺ T cell on its surface. Which class of MHC molecule is displaying this peptide, and through which specialized process did the dendritic cell load the exogenous viral antigen onto this MHC class?

Show answer

The viral peptide is displayed on MHC class I because CD8⁺ T cells are MHC I–restricted. Since the dendritic cell is presenting an exogenous antigen on MHC I (rather than the typical endogenous pathway), this occurs through cross-presentation. In this process, phagocytosed viral material escapes the endosome into the cytosol, where it is degraded by the proteasome and loaded onto MHC I via TAP. Cross-presentation is a unique capability of dendritic cells and is critical for initiating CD8⁺ cytotoxic responses against viruses that do not directly infect APCs.

Question 2: BASIC CALCULATION

A patient is heterozygous at all three classical MHC class I loci (HLA-A, HLA-B, HLA-C) and all three classical MHC class II loci (HLA-DP, HLA-DQ, HLA-DR). Due to codominant expression, how many distinct MHC class I molecules and how many distinct MHC class II molecules can this individual express on a single cell?

Show answer

For MHC class I: there are 3 loci × 2 alleles (codominant) = 6 distinct MHC class I molecules per cell. For MHC class II: each locus encodes both an α and β chain, and because MHC II chains are heterodimers, α and β chains from the same locus (and sometimes between loci) can pair. In the simplest calculation considering only cis-pairing at 3 loci × 2 alleles = 6 distinct MHC class II molecules, but with trans-complementation (α from one allele pairing with β from the other allele at the same locus), this can reach up to 12 or more combinations for class II. USMLE typically expects the answer of 6 for class I and notes that class II can generate more diversity through combinatorial α-β pairing.

Question 3: INTERMEDIATE

A researcher finds that a mutant cell line lacks functional TAP1 protein. Predict the effect on: (a) MHC class I surface expression, (b) MHC class II surface expression, (c) CD8⁺ T-cell activation, and (d) CD4⁺ T-cell activation.

Show answer

(a) MHC class I surface expression will be markedly reduced because TAP is required to transport proteasome-generated peptides into the ER for loading onto MHC I. Without peptide loading, empty MHC I molecules are unstable and are degraded or retained in the ER. (b) MHC class II surface expression will be unaffected because the exogenous pathway does not depend on TAP; peptides are loaded from acidified endosomes, not from the cytosol via the ER. (c) CD8⁺ T-cell activation will be severely impaired because CD8⁺ T cells require MHC I–peptide complexes for TCR engagement. (d) CD4⁺ T-cell activation will be normal because it depends on MHC II, which functions independently of TAP. This scenario models Bare Lymphocyte Syndrome Type I.

Question 4: APPLIED

A 35-year-old woman with rheumatoid arthritis has elevated IL-17 levels in her synovial fluid. Her rheumatologist starts her on secukinumab. Explain the immunologic rationale for this therapy, including which T-helper subset is driving joint inflammation, the transcription factor involved, and the cytokines that originally polarized this subset.

Show answer

The elevated IL-17 indicates a dominant Th17 response in the joints. Th17 cells differentiate from naïve CD4⁺ T cells under the influence of TGF-β and IL-6 (with IL-23 promoting maintenance and expansion), using the master transcription factor RORγt. Th17 cells secrete IL-17A, IL-17F, and IL-22, which recruit neutrophils to the synovium and promote osteoclast activation, driving joint destruction. Secukinumab is a monoclonal antibody that neutralizes IL-17A, thereby blocking the downstream pro-inflammatory cascade at the effector cytokine level. This targeted approach disrupts Th17-mediated pathology while leaving other arms of the adaptive immune system relatively intact, though patients should be monitored for increased susceptibility to mucocutaneous candidiasis, since Th17 responses are critical for defense against extracellular fungi.

Question 5: CRITICAL THINKING

Some tumors downregulate MHC class I expression to evade CD8⁺ cytotoxic T-cell recognition. However, these tumors become more susceptible to killing by natural killer (NK) cells. Explain why MHC I downregulation creates vulnerability to NK cells, and discuss how checkpoint inhibitor therapy (e.g., anti-PD-1) addresses the scenario where tumors retain MHC I but instead suppress T-cell function through inhibitory signaling. How might a combined immunotherapy approach address both evasion strategies?

Show answer

NK cells operate under the 'missing self' hypothesis: their killer inhibitory receptors (KIRs) normally recognize self-MHC I molecules and deliver inhibitory signals that prevent NK-mediated killing. When a tumor cell downregulates MHC I, this inhibitory signal is lost, and the NK cell's activating receptors (e.g., NKG2D recognizing stress ligands) dominate, leading to target cell lysis. However, tumors that retain MHC I can evade both CTL and NK killing by upregulating PD-L1, which engages PD-1 on activated CD8⁺ T cells and delivers an inhibitory signal that causes T-cell exhaustion. Anti-PD-1 antibodies (nivolumab, pembrolizumab) block this interaction, restoring CTL effector function. A combined approach using checkpoint inhibitors (to reactivate CTLs against MHC I–positive tumor cells) alongside strategies that enhance NK cell activity (such as anti-KIR antibodies or IL-15 agonists) would address both evasion mechanisms simultaneously, creating a comprehensive antitumor immune response regardless of tumor MHC I status.

SUMMARY

Comprehensive Summary

Summary

Antigen presentation is the process by which MHC class I molecules display endogenous peptides (processed via the proteasome and TAP transporter) to CD8⁺ cytotoxic T cells, while MHC class II molecules on professional APCs display exogenous peptides (processed via endosomal proteolysis, with invariant chain/CLIP replaced by HLA-DM) to CD4⁺ helper T cells. Dendritic cells uniquely perform cross-presentation, loading exogenous antigens onto MHC I to activate CD8⁺ T cells against non-infecting pathogens and tumors.

Full T-cell activation requires three signals: Signal 1 (TCR–MHC-peptide), Signal 2 (co-stimulation via B7–CD28), and Signal 3 (the cytokine milieu determining Th subset differentiation). Th1 (T-bet, IFN-γ) activates macrophages against intracellular pathogens; Th2 (GATA-3, IL-4/IL-5) drives IgE class switching and eosinophil responses against parasites; Th17 (RORγt, IL-17) recruits neutrophils against extracellular bacteria and fungi; and Tregs (FoxP3, IL-10/TGF-β) maintain peripheral tolerance and suppress autoimmunity. Defects in these pathways underlie Bare Lymphocyte Syndromes, and pharmacologic manipulation of co-stimulation and cytokine signaling forms the basis of modern immunotherapy including checkpoint inhibitors, anti-cytokine biologics, and transplant immunosuppression.